BioMarin Pharmaceutical vs Neurocrine Biosciences
BMRN and NBIX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRN and NBIX compare
Neurocrine Biosciences is the larger company, worth 1.5 times as much as BioMarin Pharmaceutical ($17.0B against $11.1B).
On earnings, Neurocrine Biosciences is cheaper: it trades at 24.8× trailing earnings, against 151× for BioMarin Pharmaceutical.
Neurocrine Biosciences grew revenue faster over the last twelve months (38.0% versus 11.2% for BioMarin Pharmaceutical).
Neurocrine Biosciences keeps more of each dollar of sales as profit, with a net margin of 19.0% compared with 2.1% at BioMarin Pharmaceutical.
Neurocrine Biosciences scores higher on the StockData Score (20 against 8 for BioMarin Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRN | NBIX |
|---|---|---|
| Size and price | ||
| Market cap | $11.1B | $17.0B |
| Share price | $57.23 | $167.40 |
| Change, 1 year | 3.5% | 14.0% |
| Change, 5 years | −37.4% | 94.6% |
| Beta (5Y) | 0.59 | 0.46 |
| Employees | 3,221 | 1,800 |
| StockData Score | ||
| Total score | 8 | 20 (better) |
| Valuation score | 1 | 4 (better) |
| Growth score | 3 | 5 (better) |
| Performance score | 2 | 5 (better) |
| Health score | 2 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 151× | 24.8× (better) |
| P/S | 3.3× (better) | 4.6× |
| P/B | 1.8× (better) | 4.4× |
| EV/EBITDA | 47.6× | 18.3× (better) |
| P/FCF | 15.0× (better) | 16.4× |
| PEG | 4.44 | 0.56 (better) |
| FCF yield | 6.7% (better) | 6.1% |
| Fair value | $30.00 | $190.74 |
| Margin of safety | −90.8% | 12.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.2% | 38.0% (better) |
| Revenue growth, 5Y average | 11.6% | 22.3% (better) |
| Net income growth (TTM) | −88.9% | 64.1% (better) |
| EPS growth (TTM) | −88.7% | 61.2% (better) |
| EPS growth, 5Y average | −16.7% | 2.3% (better) |
| Profitability | ||
| Gross margin | 76.1% | 97.7% (better) |
| Operating margin | 4.4% | 24.0% (better) |
| Net margin | 2.1% | 19.0% (better) |
| FCF margin | 21.7% | 28.1% (better) |
| Return on equity | 1.2% | 20.4% (better) |
| Return on invested capital | 1.0% | 26.6% (better) |
| Financial health | ||
| Debt / equity | 0.66 (better) | 0.00 |
| Net debt / EBITDA | 10.96 | – |
| Interest coverage | 2.0× | – |
| Current ratio | 2.39 (better) | 2.04 |
| Altman Z-score | 1.84 | 7.44 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | – | −0.08% |
| Shareholder yield | 0.00% (better) | −0.08% |
| Ownership | ||
| Held by institutions | 101% | 99.5% |
| Held by insiders | 0.52% | 1.2% |
| Insider net buying, 12 months | −$4.3M (better) | −$74.4M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 7.3% | 5.9% |
Go deeper
- BMRN stock overview
- BMRN income statement
- BMRN valuation and score
- NBIX stock overview
- NBIX income statement
- NBIX valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.